Osterweis Capital Management Inc. Makes New $6.73 Million Investment in Amicus Therapeutics, Inc. $FOLD

Key Points

• Osterweis Capital Management Inc. has acquired a new stake in Amicus Therapeutics, Inc., purchasing approximately 824,740 shares valued at around $6.73 million during the first quarter.
• Amicus Therapeutics received mixed ratings from analysts, with Morgan Stanley upgrading its rating to "overweight," while Wall Street Zen downgraded it to "hold," resulting in a consensus rating of "Moderate Buy."
• The stock currently trades at $8.02, with a market capitalization of $2.47 billion and a 52-week range between $5.51 and $12.65.

Osterweis Capital Management Inc. bought a new position in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 824,740 shares of the biopharmaceutical company's stock, valued at approximately $6,730,000. Osterweis Capital Management Inc. owned 0.27% of Amicus Therapeutics as of its most recent SEC filing.

Several other institutional investors also recently bought and sold shares of the stock. Nuveen LLC acquired a new stake in shares of Amicus Therapeutics during the 1st quarter worth approximately $28,741,000. Vestal Point Capital LP purchased a new stake in Amicus Therapeutics during the fourth quarter worth $31,557,000. Millennium Management LLC grew its position in Amicus Therapeutics by 635.1% during the first quarter. Millennium Management LLC now owns 3,359,389 shares of the biopharmaceutical company's stock valued at $27,413,000 after buying an additional 2,902,375 shares during the period. Redmile Group LLC grew its position in Amicus Therapeutics by 35.1% during the first quarter. Redmile Group LLC now owns 9,533,669 shares of the biopharmaceutical company's stock valued at $77,795,000 after buying an additional 2,478,779 shares during the period. Finally, Prosight Management LP purchased a new position in Amicus Therapeutics in the fourth quarter valued at $8,666,000.

Amicus Therapeutics Price Performance

NASDAQ FOLD traded up $0.04 during mid-day trading on Wednesday, hitting $8.05. The stock had a trading volume of 1,750,649 shares, compared to its average volume of 3,868,041. The firm's 50 day moving average is $7.01 and its 200 day moving average is $6.98. The company has a debt-to-equity ratio of 1.92, a current ratio of 3.21 and a quick ratio of 2.29. The stock has a market capitalization of $2.48 billion, a price-to-earnings ratio of -66.95 and a beta of 0.55. Amicus Therapeutics, Inc. has a twelve month low of $5.51 and a twelve month high of $12.65.

Wall Street Analysts Forecast Growth

Several equities analysts recently weighed in on the company. Wall Street Zen lowered Amicus Therapeutics from a "buy" rating to a "hold" rating in a research note on Saturday, August 30th. Morgan Stanley raised Amicus Therapeutics from an "equal weight" rating to an "overweight" rating in a report on Thursday, July 17th. Seven equities research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company's stock. Based on data from MarketBeat.com, Amicus Therapeutics has an average rating of "Moderate Buy" and an average price target of $16.00.

Amicus Therapeutics Company Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.